Navigation Links
Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinson's
Date:2/18/2010

German-American consortium to test nicotine patch in 150 PD patients

NEW YORK, Feb. 18 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded $1.1 million for an international clinical trial vetting the potential of a nicotine skin patch to modify the progression of Parkinson's disease. The funding was made under the Clinical Intervention Awards initiative, one of MJFF's Edmond J. Safra Core Programs for PD Research.

This first-ever multisite, investigator-initiated collaboration between Parkinson's study groups in Germany and the United States will encompass a one-year double-blind, placebo-controlled trial in 150 newly diagnosed Parkinson's patients. Principal investigators Wolfgang H. Oertel and Marcus M. Unger of Philipps University Marburg, Germany, and Karl Kieburtz of the University of Rochester, New York, will evaluate the disease-modifying potential of transdermal nicotine using standard skin patches of the type used by millions of smokers as a quitting aid. The production of the patches being used in this trial has been supported by the pharmaceutical company Novartis.

While scientists have previously studied the symptomatic effects of nicotine in Parkinson's patients, this is the first long-term clinical trial expressly designed to test whether nicotine may in fact modify the progression of PD. Parkinson's researchers have long been intrigued by epidemiological research showing a possible link between cigarette smoking and a lowered risk of PD: the disease is far less prevalent among smokers compared to never-smokers. Nicotine also has demonstrated beneficial effects on PD in pre-clinical studies. Yet key questions about the relationship among smoking, nicotine and Parkinson's — including whether smoking tobacco products in fact confers protection and, if so, whether this protection stems from the nicotine in those products — remain unanswered.

Until this trial provides data on the safety profile of transdermal nicotine in never-smokers, the study leaders caution that patients should not introduce nicotine into their treatment regimen without the explicit recommendation of their doctor. The benefits of transdermal nicotine for PD have not yet been conclusively proven, and its safety for use in people who have never smoked remains unestablished. Trial participants will be closely monitored for any adverse health effects that may occur as a result of nicotine treatment.

The commercialization of a therapy capable of retarding or stopping the progression of Parkinson's disease — rather than merely masking symptoms while the underlying disease continues to worsen — would be a transformative event in the lives of the estimated 5 million Parkinson's patients worldwide. Transdermal nicotine holds the additional advantages of wide availability and relatively low cost.

As with all MJFF awards, continued funding is dependent on researchers' achieving predetermined milestones. Progress and outcome reports will be posted to the Foundation's Web site as they become available.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded almost $176 million in research to date. 

SOURCE Michael J. Fox Foundation


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: